Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024)

Historic Non Operating Investment Income for Tango Therapeutics (TNGX) over the last 5 years, with Q1 2024 value amounting to -$443000.0.

  • Tango Therapeutics' Non Operating Investment Income fell 12945.48% to -$443000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $1.9 million, marking a year-over-year increase of 6079.4%. This contributed to the annual value of $150000.0 for FY2024, which is 9614.49% down from last year.
  • As of Q1 2024, Tango Therapeutics' Non Operating Investment Income stood at -$443000.0, which was down 12945.48% from $867000.0 recorded in Q4 2023.
  • Tango Therapeutics' Non Operating Investment Income's 5-year high stood at $1.5 million during Q1 2023, with a 5-year trough of -$2.6 million in Q1 2022.
  • Moreover, its 5-year median value for Non Operating Investment Income was -$9000.0 (2020), whereas its average is -$17866.7.
  • Its Non Operating Investment Income has fluctuated over the past 5 years, first crashed by 1773333.33% in 2022, then skyrocketed by 26424.36% in 2023.
  • Quarter analysis of 5 years shows Tango Therapeutics' Non Operating Investment Income stood at -$9000.0 in 2020, then crashed by 8288.89% to -$755000.0 in 2021, then skyrocketed by 252.45% to $1.2 million in 2022, then decreased by 24.67% to $867000.0 in 2023, then tumbled by 151.1% to -$443000.0 in 2024.
  • Its last three reported values are -$443000.0 in Q1 2024, $867000.0 for Q4 2023, and $836000.0 during Q3 2023.